Advances in evaluation of primary brain tumors.
暂无分享,去创建一个
[1] W. Nyhan,et al. The uptake of a variety of amino acids into nuclear proteins of tumors and other tissues. , 1959, Cancer research.
[2] K. Isselbacher. Sugar and amino acid transport by cells in culture--differences between normal and malignant cells. , 1972, The New England journal of medicine.
[3] A. J. Varghese,et al. The biological properties of reduced nitroheterocyclics and possible underlying biochemical mechanisms. , 1986, Biochemical pharmacology.
[4] M. Senda,et al. Re-evaluation of amino acid PET studies: can the protein synthesis rates in brain and tumor tissues be measured in vivo? , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[5] J. Cairncross,et al. Corticosteroid-induced magnetic resonance imaging changes in patients with recurrent malignant glioma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] N. Sadato,et al. Enhanced Detection of Brain Tumors by [18F]Fluorodeoxyglucose PET with Glucose Loading , 1994, Journal of computer assisted tomography.
[7] W. Olivero,et al. The use of PET in evaluating patients with primary brain tumours: is it useful? , 1995, Journal of neurology, neurosurgery, and psychiatry.
[8] T K Lewellen,et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. , 1996, International journal of radiation oncology, biology, physics.
[9] O. Witte,et al. Radiation necrosis or recurrence. , 1996, Journal of neurosurgery.
[10] S. Goldman,et al. Prognostic value positron emission tomography with [18F]fluoro-2-deoxy-D-glucose in the low-grade glioma. , 1996, Neurosurgery.
[11] J. Slattery,et al. Chemotherapy response criteria in malignant glioma , 1997, Neurology.
[12] Otto Muzik,et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography , 1998, Nature Medicine.
[13] A. Thiel,et al. 11C-methionine PET for differential diagnosis of low-grade gliomas , 1998, Neurology.
[14] B. Drayer,et al. Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography? , 1998, AJNR. American journal of neuroradiology.
[15] R. Blasberg,et al. “Facilitated” Amino Acid Transport is Upregulated in Brain Tumors , 1998, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[16] A. Alavi,et al. Can the standardized uptake value characterize primary brain tumors on FDG-PET? , 1999, European Journal of Nuclear Medicine.
[17] L. Deangelis,et al. Long-term outcome of low-grade oligodendroglioma and mixed glioma , 2000, Neurology.
[18] Wolfgang A. Weber,et al. O-(2-[18F]Fluoroethyl)-l-tyrosine and l-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study , 2000, European Journal of Nuclear Medicine.
[19] J. Brown,et al. Therapeutic targets in radiotherapy. , 2001, International journal of radiation oncology, biology, physics.
[20] Jae Jeong,et al. Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET , 2002, European Journal of Nuclear Medicine and Molecular Imaging.
[21] W Vaalburg,et al. Radiolabeled amino acids: basic aspects and clinical applications in oncology. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[22] G. Barnett,et al. The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery , 2001, International journal of cancer.
[23] W. Oyen,et al. Fluorinated amino acids for tumour imaging with positron emission tomography , 2002, European Journal of Nuclear Medicine and Molecular Imaging.
[24] Y. Yonekura,et al. Basis of FLT as a cell proliferation marker: comparative uptake studies with [3H]thymidine and [3H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines. , 2002, Nuclear medicine and biology.
[25] L. Wiens,et al. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[26] David A Mankoff,et al. Volumetric analysis of 18F-FDG PET in glioblastoma multiforme: prognostic information and possible role in definition of target volumes in radiation dose escalation. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[27] Thomas Czech,et al. Brain tumour imaging with PET: a comparison between [18F]fluorodopa and [11C]methionine , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[28] W. Burchert,et al. 3-O-Methyl-6-[18F]fluoro-l-DOPA and its evaluation in brain tumour imaging , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[29] Thomas K Lewellen,et al. 18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[30] D. Hwang,et al. Prediction of Pathology and Survival by FDG PET in Gliomas , 2003, Journal of Neuro-Oncology.
[31] Jae Seung Kim,et al. [18F]3′-deoxy-3′-fluorothymidine PET for the diagnosis and grading of brain tumors , 2005, European Journal of Nuclear Medicine and Molecular Imaging.
[32] T. Turkington,et al. PET and brain tumor image fusion. , 2004, Cancer journal.
[33] B. Weber,et al. Uptake of 18F-fluorocholine, 18F-fluoroethyl-L-tyrosine, and 18F-FDG in acute cerebral radiation injury in the rat: implications for separation of radiation necrosis from tumor recurrence. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[34] Jörg-Christian Tonn,et al. Value of O-(2-[18F]fluoroethyl)-l-tyrosine PET for the diagnosis of recurrent glioma , 2004, European Journal of Nuclear Medicine and Molecular Imaging.
[35] S. Goldman,et al. Combined use of 18F-fluorodeoxyglucose and 11C-methionine in 45 positron emission tomography-guided stereotactic brain biopsies. , 2004, Journal of neurosurgery.
[36] K. Herfarth,et al. PET and SPECT for detection of tumor progression in irradiated low-grade astrocytoma: a receiver-operating-characteristic analysis. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[37] S. Ametamey,et al. Assessment of hypoxia and perfusion in human brain tumors using PET with 18F-fluoromisonidazole and 15O-H2O. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[38] Isabelle Salmon,et al. Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[39] Karl-Josef Langen,et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. , 2005, Brain : a journal of neurology.
[40] Morand Piert,et al. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. , 2004, International journal of radiation oncology, biology, physics.
[41] W. Koch,et al. Positron Emission Tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus Magnetic Resonance Imaging in the Diagnosis of Recurrent Gliomas , 2005, Neurosurgery.
[42] Marvin Bergsneider,et al. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[43] Hans-Jakob Steiger,et al. Multimodal metabolic imaging of cerebral gliomas: positron emission tomography with [18F]fluoroethyl-L-tyrosine and magnetic resonance spectroscopy. , 2005, Journal of neurosurgery.
[44] Karl Herholz,et al. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[45] Mark Muzi,et al. [F-18]-fluorodeoxyglucose positron emission tomography for targeting radiation dose escalation for patients with glioblastoma multiforme: clinical outcomes and patterns of failure. , 2006, International journal of radiation oncology, biology, physics.
[46] T. Turkington,et al. 3′-Deoxy-3′-[F-18]Fluorothymidine Positron Emission Tomography in Patients with Recurrent Glioblastoma Multiforme: Comparison with Gd-DTPA Enhanced Magnetic Resonance Imaging , 2006, Molecular Imaging and Biology.
[47] T. Manabe,et al. Evaluation of Primary Brain Tumors With FLT-PET: Usefulness and Limitations , 2006, Clinical nuclear medicine.
[48] Wei Chen,et al. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[49] Sung-Cheng Huang,et al. 18F-fluorothymidine kinetics of malignant brain tumors , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[50] G. Reifenberger,et al. 18F-FET PET differentiation of ring-enhancing brain lesions. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[51] S. Berlangieri,et al. Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[52] G. Reifenberger,et al. Differential uptake of [18F]FET and [3H]l-methionine in focal cortical ischemia. , 2006, Nuclear medicine and biology.
[53] K. Ericson,et al. FDG-PET on irradiated brain tumor: ten years' summary , 2006, Acta radiologica.
[54] M. Watters,et al. Solitary brain lesions enhancing at MR imaging: evaluation with fluorine 18 fluorocholine PET. , 2007, Radiology.
[55] Wei Chen,et al. Positron Emission Tomography in Patients With Central Motor Disorders and in Evaluation of Brain and Other Tumors , 2007 .
[56] A. von Deimling,et al. Association between fluorine-18-labeled fluorodeoxyglucose uptake and 1p and 19q loss of heterozygosity in World Health Organization Grade II gliomas. , 2007, Journal of neurosurgery.
[57] Wei Chen,et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] N. Shah,et al. Differential Uptake of O-(2-18F-Fluoroethyl)-l-Tyrosine, l-3H-Methionine, and 3H-Deoxyglucose in Brain Abscesses , 2007, Journal of Nuclear Medicine.
[59] Wei Chen,et al. 18F-FDOPA Kinetics in Brain Tumors , 2007, Journal of Nuclear Medicine.
[60] V. Treyer,et al. Spatial Heterogeneity of Low-Grade Gliomas at the Capillary Level: A PET Study on Tumor Blood Flow and Amino Acid Uptake , 2007, Journal of Nuclear Medicine.
[61] T Metens,et al. Stereotactic comparison among cerebral blood volume, methionine uptake, and histopathology in brain glioma. , 2007, AJNR. American journal of neuroradiology.
[62] J. Cizek,et al. Evaluation of Primary Brain Tumors Using 11C-Methionine PET with Reference to a Normal Methionine Uptake Map , 2007, Journal of Nuclear Medicine.